

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/889,645
				Filing Date	01/24/2002
				First Named Inventor	Anne Gillian Welch
				Group Art Unit	1648
Examiner Name	Agnieszka Boesen				
Sheet	F1	of	F2	Attorney Docket Number	9013-31

<b>U.S. PATENTS AND PATENT PUBLICATIONS</b>					
Examiner Initials *	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1.	US-4,278,551		Hou et al.	07/14/1981
	2.	US-4,288,462		Hou et al.	09/08/1981
	3.	US-4,309,427		Hou et al.	01/05/1982
	4.	US-6,627,088	B1	Breitenbach et al.	09/30/2003

<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			
	5.	EP	0734285	B1	Breitenbach et al.	06/03/1998	N

<b>OTHER NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T
	6.	Statement from Pall Corporation regarding the charge properties of the filter types KS80 and K200 P according to the invention, dated February 25, 2005 (5 pages).	
	7.	Experimental data from ZLB Behring GmbH (1 page)	
	8.	Brochures concerning Seitz filters (19 pages)	
	9.	Flan et al. "Evaluation of TSE removal procedures in the manufacture of plasma products", <u>Who Consultation on Tissue Infectivity Distribution in TSEs</u> (29 pages) (2005)	
	10.	Further statement from Pall Corporation regarding the charge properties of the filter types KS80 and K200 P according to the invention, dated March 26, 2007.	
	11.	New test results from CSL Behring GmbH (5 pages)	
	12.	EMEA document "CHMP Position Statement on Creutzfeldt-Jakob Disease and Plasma-Derived and Urine-Derived Medicinal Products" (17 pages) (2004)	
	13.	Patel et al. "Creating lipid-free protein solutions", <u>Manufacturing Chemist</u> pps. 34-35 (1992)	
	14.	Hou et al. "Lipid Removal from Protein Solution by Depth Filter", <u>Fluid/Particle Separation Journal</u> pps. 108-110 (1998)	
	15.	Patel "Charge Modified Depth Filter - Technology and its Evolution", <u>Filtration &amp; Separation</u> pps. 221-226 (1992)	
	16.	Brown et al. "Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans", <u>Transfusion</u> 39:1169-1178 (1999)	
	17.	Meltzer "Depth-Type Filters", <u>Filtration in the Pharmaceutical Industry Marcel Dekker, Inc.</u> pps. 8-9, 14-15, and 17	
	18.	Mandaro "Charge-Modified Depth Filters: Cationic-Charge-Modified Nylon Membranes", <u>Filtration in the Pharmaceutical Industry Marcel Dekker, Inc. Chapter 5:183-207</u>	
	19.	"Filtrative Particle Removal from Liquids", <u>Filtration in the Pharmaceutical Industry Marcel Dekker, Inc. Chapter 8:299-305</u>	
	20.	Seitz Filtration K200 Quality Specification (3 pages) (1989)	
	21.	Cuno Zeta Plus Filter Media (2 pages) (1999)	
	22.	Notice of Opposition by ZLB Behring GmbH in European Patent No. 1144015 B1 (2005)	
	23.	Appeal by CSL Behring GmbH in European Patent No. 1144015 B1 (2007)	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

				Application Number	09/889,645
				Filing Date	01/24/2002
				First Named Inventor	Anne Gillian Welch
				Group Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	F2	of	F2	Attorney Docket Number	9013-31

	24.	Letter from Pall Corporation to CSL Behring dated March 26, 2007.	
	25.	Report on studies for verifying the examples in EP 1144015 B1	
	26.	Decision to maintain the European patent in amended form in European Patent No. 1144015 B1 dated October 21, 2010.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through